NCT00764751

Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris

LEO 19123 Cream in the Treatment of Psoriasis Vulgaris

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: LEO Pharma · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will compare the efficacy and safety of once daily treatment of LEO 19123 cream versus Dovonex® cream (applied twice daily) and versus LEO 19123 cream vehicle alone (applied twice daily) in subjects with psoriasis vulgaris. Subject will be treated for 4 weeks. All subjects will apply LEO 19123 cream to psoriasis lesions on the left or right side of the body and either Dovonex® cream or cream vehicle to lesions on the other side.

Conditions

• Psoriasis Vulgaris

Interventions

Type	Name	Description
DRUG	LEO 19123 Cream (calcipotriol plus LEO 80122)	Once daily application
DRUG	Dovonex® cream	Twice daily application
DRUG	Cream vehicle	Twice daily application

Timeline

• Start date: 2008-09-01
• Primary completion: 2008-12-01
• Completion: 2009-01-01
• First posted: 2008-10-02
• Last updated: 2025-03-07
• Results posted: 2019-05-06

Locations

1 site across 1 country: Canada